GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLASCO Taiwan Co Ltd (ROCO:6662) » Definitions » EV-to-EBIT

BioLASCO Taiwan Co (ROCO:6662) EV-to-EBIT : 13.36 (As of May. 16, 2024)


View and export this data going back to 2018. Start your Free Trial

What is BioLASCO Taiwan Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, BioLASCO Taiwan Co's Enterprise Value is NT$789.9 Mil. BioLASCO Taiwan Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was NT$59.1 Mil. Therefore, BioLASCO Taiwan Co's EV-to-EBIT for today is 13.36.

The historical rank and industry rank for BioLASCO Taiwan Co's EV-to-EBIT or its related term are showing as below:

ROCO:6662' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.14   Med: 11.55   Max: 35.34
Current: 12.48

During the past 10 years, the highest EV-to-EBIT of BioLASCO Taiwan Co was 35.34. The lowest was 6.14. And the median was 11.55.

ROCO:6662's EV-to-EBIT is ranked worse than
54.33% of 427 companies
in the Biotechnology industry
Industry Median: 10.05 vs ROCO:6662: 12.48

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. BioLASCO Taiwan Co's Enterprise Value for the quarter that ended in Mar. 2024 was NT$796.6 Mil. BioLASCO Taiwan Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was NT$59.1 Mil. BioLASCO Taiwan Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 7.42%.


BioLASCO Taiwan Co EV-to-EBIT Historical Data

The historical data trend for BioLASCO Taiwan Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLASCO Taiwan Co EV-to-EBIT Chart

BioLASCO Taiwan Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.14 9.25 10.55 11.13 11.17

BioLASCO Taiwan Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.44 11.45 12.47 11.17 -

Competitive Comparison of BioLASCO Taiwan Co's EV-to-EBIT

For the Biotechnology subindustry, BioLASCO Taiwan Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLASCO Taiwan Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLASCO Taiwan Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BioLASCO Taiwan Co's EV-to-EBIT falls into.



BioLASCO Taiwan Co EV-to-EBIT Calculation

BioLASCO Taiwan Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=789.869/59.108
=13.36

BioLASCO Taiwan Co's current Enterprise Value is NT$789.9 Mil.
BioLASCO Taiwan Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$59.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLASCO Taiwan Co  (ROCO:6662) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

BioLASCO Taiwan Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=59.108/796.5853
=7.42 %

BioLASCO Taiwan Co's Enterprise Value for the quarter that ended in Mar. 2024 was NT$796.6 Mil.
BioLASCO Taiwan Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$59.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLASCO Taiwan Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of BioLASCO Taiwan Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLASCO Taiwan Co (ROCO:6662) Business Description

Traded in Other Exchanges
N/A
Address
3rd Floor, 316 Chong-yang Road, Taipei, TWN, 115
BioLASCO Taiwan Co Ltd is a biological experimental development company. The company has produced strains of laboratory rats and mice, including outbreed stocks, inbreed strains, and immunedeficient models. It offers reagent kit and equipment which include Allentown, Biomedical data system, PLAS LABS.

BioLASCO Taiwan Co (ROCO:6662) Headlines

No Headlines